Lecozotan

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Lecozotan
Lecozotan structure.svg
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
Formula C28H30ClN5O3
Molar mass 520.021 g/mol
3D model (JSmol)
  (verify)

Lecozotan is an investigational drug by Wyeth tested for improvement of cognitive functions of Alzheimer's disease patients.[1] As of June 2008, the first Phase III clinical trial has been completed.[2]

Method of action[edit]

Lecozotan is a competitive, selective 5-HT1A receptor antagonist[3] which enhances the potassium-stimulated release of acetylcholine and glutamate.[4]

References[edit]

  1. ^ H. Spreitzer (August 13, 2008). "Neue Wirkstoffe - Lecozotan". Österreichische Apothekerzeitung (in German) (17/2007): 805. 
  2. ^ ClinicalTrials
  3. ^ Schlechter, LE; Smith, DL; Rosenzweig-Lipson, S; Sukoff, SJ; Dawson, LA; Marquis, K; Jones, D; Piesla, M; et al. (June 10, 2005). "Lecotozan (SRA-333): A selective serotonin1A receptor antagonist that enhances the stimulated release of glutamate and acetylcholine in the hippocampus and promotes procognitive effects". Journal of Pharmacology and Experimental Therapeutics. 314 (3): 1274–89. doi:10.1124/jpet.105.086363. PMID 15951399. 
  4. ^ Childers, WE Jr, Harrison, BL, Abou-Gharbia, MA, Raje, S, Parks, V, Pangalos, MN, Schechter, LE (2007). "Lecozotan Hydrochloride". Drugs of the Future. 32 (5): 399–407. doi:10.1358/dof.2007.032.05.1092901.